

FE DE ERRATAS

Por un lamentable error en un Artículo Original de la Revista MÉDICAS UIS publicado en el N° 3 de 2016 (MÉD. UIS. 2016;29(3):13-25) existe una errata en el proceso de diagramación del artículo **“Efectividad del tratamiento con Alveofact® y Curosurf® en prematuros de 32 semanas o menos con enfermedad de membrana hialina en Buga, Valle del Cauca, entre los años 2006 y 2013”**. La errata consiste en que se alteró la bibliografía utilizada dentro del mismo, omitiéndose las referencias 43 a la 50. A continuación se presenta la corrección realizada al apartado de Referencias Bibliográficas, donde dice:

REFERENCIAS BIBLIOGRÁFICAS

1. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. *AMA J Dis Child* 1959;97: 517-523.
2. EuroNeoStat Annual Report for Very Low Gestational Age Infants 2010. The ENS Project. Hospital de Cruces, Unidad Neonatal 5-D, Plaza de Cruces s/n, 48903 Barakaldo, Spain. Info.euroneonet@euskalnet.net.
3. Sinha S, Gupta S and Donn S. Immediate respiratory management of the preterm infant. *Seminars in Fetal and Neonatal Medicine*. 2008;13:24-29.
4. Logan JW, Moya FR. Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trials. *Ther Clin Risk Manag* 2009;5: 251-260.
5. Pfister RH, Soll RF, Wiswell T. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. *Cochrane Database Syst Rev*. 2007;(4): CD006069.
6. Ramanathan R. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials. *J Perinatol* 2009;29 Suppl:2: S38-43.
7. Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. *Cochrane Database Syst Rev*. 2009;(2): CD007836.
8. Nouraeyan N, A Lambrinakos-Raymond, M Leone, G Sant'Anna. Surfactant administration in neonates: A review of delivery methods. *Can J Respir Ther* 2014;50(3):91-95.
9. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. *Cochrane Database Syst Rev*. 2001;(2):CD000144.
10. Clark RH, Auten RL, Peabody J. A comparison of the outcomes of neonates treated with two different natural surfactants. *J Pediatr* 2001;139:828-31.
11. Baroutis G, Kaleyias J, Liarou T, Papatoma E, Hatzistamatiou Z, Costalos C. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. *Eur J Pediatr* 2003;162:476-80.
12. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. *Cochrane Database Syst Rev*. 2000;(2):CD001079.
13. Soll R. Synthetic surfactant for respiratory distress syndrome in preterm infants. *Cochrane Database Syst Rev*. 2000;(2): CD001149.
14. Soll R, Ozek E. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. *Cochrane Database Syst Rev*. 2009;(1):CD000141.
15. Ikegami M, Agata Y, Elkady T, Hallman M, Berry D, Jobe A. Comparison of four surfactants: in vitro surface properties and responses of preterm lambs to treatment at birth. *Pediatrics* 1987;79:38-46.
16. Frerking I, Günther A, Seeger W and Pison U. Pulmonary surfactant: functions, abnormalities and therapeutic options. *Intensive Care Med* 2001;27:1699-1717. doi: 10.1007/s00134-001-1121-5.
17. Polin RA, Waldemar AC, committee on fetus and newborn. Surfactant replacement therapy for preterm and term neonates with respiratory distress. *Clinical report. Pediatrics* 2014; 133(1):156-63. doi: 10.1542/peds.2013-3443. Epub 2013 Dec 30.
18. Mendoza LA, Oliveros M, Osorio MA, Arias M, Ruiz Y, Arce D y cols. Eficacia de tres tipos de surfactante exógeno en prematuros con enfermedad de membrana hialina. *Rev Chil Pediatr* 2013; 84 (6): 616-627.
19. Bernhard W, Mottaghian J, Gebert A, Rau GA, von der Hardt H, and Poets CH F. Commercial versus Native Surfactants Surface Activity, Molecular Components, and the Effect of Calcium. *Am J Respir Crit Care Med* 2000.162:1524-1533.
20. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, et al. European Consensus Guidelines on the Management of Neonatal Respiratory Distress Syndrome in Preterm Infants – 2013 Update. *Neonatology* 2013;103:353-368. doi: 10.1159/000349928.
21. Cloete E., Lo C., Buksh, M.J. Respiratory outcomes following 100 mg/kg v. 200 mg/kg of poractant alpha: A retrospective review. *S Afr J CH* 2013;7(4):148-152. doi:10.7196/SAJCH.634.
22. Proquitté H, Dushe Th, Hammer H, Rüdiger M, Schmalisch G, and Wauer RR. Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants. *Respiratory Medicine* 2007;101:169-176.
23. Ramanathan R, Kamholz K, Fujii AM. Is there a Difference in Surfactant Treatment of Respiratory Distress Syndrome in Premature Neonates? A Review. *J Pulmon Resp Med*. 2013; S13: 004. doi:10.4172/2161-105X.S13-004.
24. Kanmaz H.G., Erdeve O, Canpolat F.E., Mutlu B. and Dilmen U. Surfactant Administration via Thin Catheter During Spontaneous Breathing: Randomized Controlled Trial. *Pediatrics* 2013;131:e502-9 doi: 10.1542/peds.2012-0603. Epub 2013 Jan 28.; doi: 10.1542/peds.2012-0603. Acceso: Junio 28 de 2016. Disponible en: <http://pediatrics.aappublications.org/content/131/2/e502.full.html>.
25. Kandiraju H, Murki S, Subramanian S, Gaddam P, Deorari A, Kumar P. Early routine versus late selective surfactant in preterm neonates with respiratory distress syndrome on nasal continuous positive airway pressure: a randomized controlled trial. *Neonatology* 2013; 103:148-154.
26. Dilmen U, Ozdemir R, Aksoy HT, Uras N, Demirel N, Kirimi E, Erdeve O, Ozer E, Baş AY, Gürsoy T, Zenciroğlu A, Ovalı F, Oğuz SS: Early regular versus late selective poractant treatment in preterm infants born between 25 and 30 gestational weeks: a prospective randomized multicentre study. *J Matern Fetal Neonatal Med* 2014;27(4):411-5. doi: 10.3109/14767058.2013.818120
27. Chung K.Y., Lee N.M., Yun S.W., Chae S.A., Lim I.S., Choi E.S., et al. Comparison of Outcomes between Prophylactic and Rescue Therapy of Surfactant in Premature Infants. *Neonatal Med* 2013;20(1):90-96.
28. Karger AG. Early versus Delayed Selective Surfactant Treatment for Neonatal Respiratory Distress Syndrome. *Neonatology* 2013;104:124-126.
29. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, et al: Early CPAP versus surfactant in extremely preterm infants. *N Engl J Med*

- 2010; 362: 1970–1979.
30. Sandri F, Plavka R, Ancora G, Simeoni U, Stranak Z, Martinelli S, et al. CURPAP Study Group: Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. *Pediatrics* 2010; 125:e1402–e1409.
 31. Rojas-Reyes MX, Morley CJ, Soll R: Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. *Cochrane Database Syst Rev*. 2012;(3):CD000510.
 32. Rich W, Finer NN, Gantz MG, Newman NS, Hensman AM, Hale EC, et al. SUPPORT and Generic Database Subcommittees of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network: Enrollment of extremely low birth weight infants in a clinical research study may not be representative. *Pediatrics* 2012; 129: 480–484.
 33. British Association of Perinatal Medicine RDS/Surfactant Guidelines Group: Guidelines for good practice in the management of respiratory distress syndrome; 1999. <http://www.bapm.org>. Engle WA, American Academy of Pediatrics Committee on Fetus and Newborn: Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. *Pediatrics* 2008; 121:419–432.
 34. Fetus and Newborn Committee, Canadian Paediatric Society: Recommendations for neonatal surfactant therapy. *Paediatr Child Health* 2005; 10:109–116.
 35. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, et al. European Association of Perinatal Medicine: European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants - 2010 update. *Neonatology* 2010; 97:402–417.
 36. Speer CP, Robertson B, Curstedt T, Halliday HL, Compagnone D, Gefeller O, et al. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. *Pediatrics* 1992; 89: 13–20.
 37. Carnielli VP, Zimmermann LJ, Hamvas A, Cogo PE. Pulmonary surfactant kinetics of the newborn infant: novel insights from studies with stable isotopes. *J Perinatol* 2009; 29(suppl 2):S29–S37.
 38. Trembath A., Hornik Ch.P., Clark C., Smith B., Daniels J., and Laughon M., On behalf of the Best Pharmaceuticals for Children Act—Pediatric Trials Network. Comparative Effectiveness of Surfactant Preparations in Premature Infants. *J Pediatr* 2013;163:955-60.
 39. Ramanathan R, Bhatia JJ, Sekar K, and Ernst FR. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study. *J Perinatol* 2013;33:119–125.
 40. Walsh B.K., Daigle B., DiBlasi R.M., and Restrepo R.D. AARC Clinical Practice Guideline. Surfactant Replacement Therapy: 2013. *Respir Care* 2013;58(2):367–375.
 41. Fujii AM. Cardiovascular Effects of the Treatment of Respiratory Distress Syndrome and Associated Morbidities of Prematurity. *J Pulmon Resp Med* 2013;S13:005. doi:10.4172/2161-105X.S13-005.
 42. Katheria AC and Leone TA. Changes in hemodynamics after rescue surfactant administration. *J Perinatol* 2013;33:525–528. doi:10.1038/jp.2012.166.
 5. Pfister RH, Soll RF, Wiswell T. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. *Cochrane Database Syst Rev*. 2009;(4):CD006069.
 6. Ramanathan R. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials. *J Perinatol* 2009;29(2 Suppl):S38-43.
 7. Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. *Cochrane Database Syst Rev*. 2009;(2):CD007836.
 8. Nouraeyan N, Lambrinakos-Raymond A, Leone M, Sant'Anna G. Surfactant administration in neonates: A review of delivery methods. *Can J Respir Ther*. 2014;50(3):91-95.
 9. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. *Cochrane Database Syst Rev*. 2001;(2):CD000144.
 10. Clark RH, Auten RL, Peabody J. A comparison of the outcomes of neonates treated with two different natural surfactants. *J Pediatr*. 2001;139(6):828–31.
 11. Baroutis G, Kaleyias J, Liarou T, Papatoma E, Hatzistamatiou Z, Costalos C. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. *Eur J Pediatr*. 2003;162(7):476–80.
 12. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. *Cochrane Database Syst Rev*. 2000;(2):CD001079.
 13. Soll R. Synthetic surfactant for respiratory distress syndrome in preterm infants. *Cochrane Database Syst Rev*. 2000;(2):CD001149.
 14. Soll R, Ozek E. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. *Cochrane Database Syst Rev*. 2009;(1):CD000141.
 15. Ikegami M, Agata Y, Elkady T, Hallman M, Berry D, Jobe A. Comparison of four surfactants: in vitro surface properties and responses of preterm lambs to treatment at birth. *Pediatrics*. 1987;79(1):38–46.
 16. Frerking I, Günther A, Seeger W, Pison U. Pulmonary surfactant: functions, abnormalities and therapeutic options. *Intensive Care Med*. 2001;27(11):1699-717.
 17. Polin RA, Waldemar AC; Comité on Fetus and Newborn; American Academy of Pediatrics. Surfactant Replacement Therapy for Preterm and Term Neonates with Respiratory Distress. *Pediatrics*. 2014; 133(1):156-63.
 18. Mendoza LA, Oliveros M, Osorio MA, Arias M, Ruiz Y, Arce D, et al. Eficacia de tres tipos de surfactante exógeno en prematuros con enfermedad de membrana hialina. *Rev Chil Pediatr*. 2013;84(6):616-27.
 19. Bernhard W, Mottaghian J, Gebert A, Rau GA, von der Hardt H, and Poets CH F. Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. *Am J Respir Crit Care Med*. 2000;162(4 Pt 1):1524-33.
 20. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, et al. European Consensus Guidelines on the Management of Neonatal Respiratory Distress Syndrome in Preterm Infants – 2013 Update. *Neonatology*. 2013;103(4):353-68.
 21. Cloete E, Lo C, Buksh MJ. Respiratory outcomes following 100 mg/kg v. 200 mg/kg of poractant alpha: A retrospective review. *SAJCH*. 2013;7(4):148-52.
 22. Proquitté H, Dushe T, Hammer H, Rüdiger M, Schmalisch G, Wauer RR. Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants. *Respir Med*. 2007;101(1):169-76.
 23. Ramanathan R, Kamholz K, Fujii AM. Is there a Difference in Surfactant Treatment of Respiratory Distress Syndrome in Premature Neonates? A Review. *J Pulmon Resp Med*. 2013; S13:004.
 24. Kanmaz HG, Erdevé O, Canpolat FE, Mutlu B, Dilmén U. Surfactant Administration via Thin Catheter During Spontaneous Breathing: Randomized Controlled Trial. *Pediatrics*. 2013;131(2):e502-9. Epub 2013 Enero 28.
 25. Kandraju H, Murki S, Subramanian S, Gaddam P, Deorari A, Kumar P. Early routine versus late selective surfactant in preterm neonates with respiratory distress syndrome on nasal continuous positive airway pressure: a randomized controlled

Debe decir:

REFERENCIAS BIBLIOGRÁFICAS

1. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. *AMA Am J Dis Child*. 1959;97(5):517-523. [Artículo de revista]
2. EuroNeoStat. Annual Report for Very Low Gestational Age Infants 2010. Barakaldo, Spain: The ENS Project.
3. Sinha S, Gupta S, Donn S. Immediate respiratory management of the preterm infant. *Semin Fetal Neonatal Med*. 2008;13:24-29.
4. Logan JW, Moya FR. Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trials. *Ther Clin Risk Manag*. 2009;5:251-260.

- trial. *Neonatology*. 2013;103(2):148–54.
26. Dilmen U, Özdemir R, Tatar HA, Uras N, Demirel N, Kirimi E, et al. Early regular versus late selective poractant treatment in preterm infants born between 25 and 30 gestational weeks: a prospective randomized multicenter study. *J Matern Fetal Neonatal Med*. 2014;27(4):411-5.
 27. Chung KY, Lee NM, Yun SW, Chae SA, Lim IS, Choi ES, et al. Comparison of Outcomes between Prophylactic and Rescue Therapy of Surfactant in Premature Infants. *Neonatal Med*. 2013;20(1):90-6.
 28. Karger AG. Early versus Delayed Selective Surfactant Treatment for Neonatal Respiratory Distress Syndrome. *Neonatology*. 2013;104:124–6.
 29. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, et al. Early CPAP versus surfactant in extremely preterm infants. *N Engl J Med* 2010; 362:1970–79.
 30. Sandri F, Plavka R, Ancora G, Simeoni U, Stranak Z, Martinelli S, et al. Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. *Pediatrics* 2010; 125(6):e1402–9.
 31. Rojas-Reyes MX, Morley CJ, Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. *Cochrane Database Syst Rev*. 2012; 14(3):CD000510.
 32. Rich W, Finer NN, Gantz MG, Newman NS, Hensman AM, Hale EC, et al. Enrollment of extremely low birth weight infants in a clinical research study may not be representative. *Pediatrics* 2012; 129(3):480–4.
 33. Engle WA, American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. *Pediatrics* 2008; 121(2):419–32.
 34. Davis DJ, Barrington KJ, Canadian Paediatric Society, Fetus and Newborn Committee. Recommendations for neonatal surfactant therapy. *Paediatr Child Health* 2005; 10(2):109–16.
 35. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants - 2010 update. *Neonatology* 2010; 97(4):402–17.
 36. Speer CP, Robertson B, Curstedt T, Halliday HL, Compagnone D, Gefeller O, et al. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. *Pediatrics* 1992; 89(1): 13–20.
 37. Carnielli VP, Zimmermann LJ, Hamvas A, Cogo PE. Pulmonary surfactant kinetics of the newborn infant: novel insights from studies with stable isotopes. *J Perinatol* 2009; 29(suppl 2):S29–37.
 38. Trembath A, Hornik CP, Clark C., Smith B, Daniels J, Laughon M, Best Pharmaceuticals for Children Act—Pediatric Trials Network. Comparative Effectiveness of Surfactant Preparations in Premature Infants. *J Pediatr* 2013; 163(4):955-60.e1.
 39. Ramanathan R., Bhatia JJ, Sekar K, Ernst FR. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study. *J Perinatol*. 2013; 33(2):119–25.
 40. Walsh BK, Daigle B, DiBlasi RM, Restrepo RD, American Association for Respiratory Care. AARC Clinical Practice Guideline. Surfactant Replacement Therapy: 2013. *Respir Care* 2013; 58(2):367–75.
 41. Fujii AM. Cardiovascular Effects of the Treatment of Respiratory Distress Syndrome and Associated Morbidities of Prematurity. *J Pulmon Resp Med* 2013; S13:005. doi:10.4172/2161-105X.S13-005.
 42. Katheria AC, Leone TA. Changes in hemodynamics after rescue surfactant administration. *J Perinatol* 2013;33:525–8.
 43. Saliba E, Nashashibi M, Vaillant MC, Nasr C, Laugier J. Instillation rate effects of Exosurf on cerebral and cardiovascular haemodynamics in preterm neonates. *Arch Dis Child Fetal Neonatal Ed* 1994; 71: F174–F178.
 44. Rabe H, Jorch G. Cerebral hemodynamics in perinatal pharmacology. *Dev Pharmacol Ther* 1991; 17: 128–132.
 45. Cowan F, Whitelaw A, Wertheim D, Silverman M. Cerebral blood flow velocity changes after rapid administration of surfactant. *Arch Dis Child* 1991; 66: 1105–1109.
 46. Roll C, Knief J, Horsch S, Hanssler L. Effect of surfactant administration on cerebral haemodynamics and oxygenation in premature infants—a near infrared spectroscopy study. *Neuropediatrics* 2000; 31: 16–23.
 47. Seppanen M, Kaapa P, Kero P. Acute effects of synthetic surfactant replacement on pulmonary blood flow in neonatal respiratory distress syndrome. *Am J Perinatol* 1994; 11: 382–385.
 48. O'Toole SJ, Karamanoukian HL, Morin FC, Holm BA, Egan EA, Azizkhan RG, et al. Surfactant decreases pulmonary vascular resistance and increases pulmonary blood flow in the fetal lamb model of congenital diaphragmatic hernia. *J Pediatr Surg* 1996; 31: 507-511.
 49. Farstad T, Bratlid D, Mødbø S, Markestad T, and The Norwegian Extreme Prematurity Study Group. Bronchopulmonary dysplasia – prevalence, severity and predictive factors in a national cohort of extremely premature infants. *Acta Paediatrica* 2011; 100:53–58.
 50. Barría M, Pino P, y Becerra C. Mortalidad en prematuros tratados con surfactante exógeno. *Rev Chil Pediatr* 2008;79(1):36-44.